[go: up one dir, main page]

WO2010036031A3 - Anticorps monoclonal humain specifique au pauf, composition pharmaceutique destinee au traitement du cancer le comprenant et procede l'utilisant pour detecter le cancer - Google Patents

Anticorps monoclonal humain specifique au pauf, composition pharmaceutique destinee au traitement du cancer le comprenant et procede l'utilisant pour detecter le cancer Download PDF

Info

Publication number
WO2010036031A3
WO2010036031A3 PCT/KR2009/005437 KR2009005437W WO2010036031A3 WO 2010036031 A3 WO2010036031 A3 WO 2010036031A3 KR 2009005437 W KR2009005437 W KR 2009005437W WO 2010036031 A3 WO2010036031 A3 WO 2010036031A3
Authority
WO
WIPO (PCT)
Prior art keywords
pauf
cancer
same
monoclonal antibody
human monoclonal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/005437
Other languages
English (en)
Other versions
WO2010036031A2 (fr
Inventor
Sang Seok Koh
Yang Soon Lee
Mi Jin Sohn
Su Jin Kim
Kyung Sook Yoo
Eun Hye Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Bioscience and Biotechnology KRIBB
Original Assignee
Korea Research Institute of Bioscience and Biotechnology KRIBB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Research Institute of Bioscience and Biotechnology KRIBB filed Critical Korea Research Institute of Bioscience and Biotechnology KRIBB
Publication of WO2010036031A2 publication Critical patent/WO2010036031A2/fr
Publication of WO2010036031A3 publication Critical patent/WO2010036031A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne une protéine PAUF associée à la formation du cancer, un anticorps monoclonal humain spécifique à la protéine PAUF, et une molécule d'acide nucléique codant pour la protéine PAUF, ainsi que leurs utilisations. Étroitement corrélée à la formation du cancer, la protéine PAUF ou la molécule d'acide nucléique de PAUF peut être utilisée comme marqueur diagnostique ou cible thérapeutique. De plus, ayant la capacité de se lier spécifiquement à PAUF présentée sur la surface de diverses cellules cancéreuses, y compris les cellules cancéreuses pancréatiques, l'anticorps anti-PAUF ou son fragment fonctionnel permet le diagnostic du cancer aux stades précoces de celui-ci et l'inhibition de sa croissance, l'invasion ou la migration des cellules cancéreuses par induction de l'apoptose chez les cellules, d'où son utilité dans le diagnostic et le traitement du cancer.
PCT/KR2009/005437 2008-09-23 2009-09-23 Anticorps monoclonal humain specifique au pauf, composition pharmaceutique destinee au traitement du cancer le comprenant et procede l'utilisant pour detecter le cancer Ceased WO2010036031A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20080093106 2008-09-23
KR10-2008-0093106 2008-09-23

Publications (2)

Publication Number Publication Date
WO2010036031A2 WO2010036031A2 (fr) 2010-04-01
WO2010036031A3 true WO2010036031A3 (fr) 2010-06-24

Family

ID=42060277

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/005437 Ceased WO2010036031A2 (fr) 2008-09-23 2009-09-23 Anticorps monoclonal humain specifique au pauf, composition pharmaceutique destinee au traitement du cancer le comprenant et procede l'utilisant pour detecter le cancer

Country Status (2)

Country Link
KR (2) KR20100034720A (fr)
WO (1) WO2010036031A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012128502A2 (fr) * 2011-03-24 2012-09-27 한국생명공학연구원 Composition contenant le facteur pauf et stimulant la vasculogenèse
KR101373103B1 (ko) * 2011-03-28 2014-03-11 연세대학교 산학협력단 Ｐａｕｆ 및 그의 결합 파트너의 상호작용을 이용한 암 치료제의 스크리닝 방법
KR101250557B1 (ko) * 2011-05-18 2013-04-03 국립암센터 Ｐａｕｆ 특이적 앱타머 및 이를 포함하는 췌장암 치료용 조성물
WO2019022274A1 (fr) * 2017-07-28 2019-01-31 동아대학교 산학협력단 Anticorps se liant spécifiquement à une protéine pauf, et utilisation associée
KR101856904B1 (ko) 2017-07-28 2018-05-11 동아대학교 산학협력단 Pauf 단백질에 특이적으로 결합하는 항체 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007145466A1 (fr) * 2006-06-14 2007-12-21 Lg Life Sciences Ltd. Famille de gène (lbfl313) associée au cancer du pancréas

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007145466A1 (fr) * 2006-06-14 2007-12-21 Lg Life Sciences Ltd. Famille de gène (lbfl313) associée au cancer du pancréas

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CLARK, H. F. ET AL.: "The secreted protein discovery initiative(SPDI), a larg e-scale effort to identify novel human secreted and transmembrane proteins: a bioinformative assessment.", GENOME RESEARCH., vol. 13, no. 10, 15 September 2003 (2003-09-15), pages 2265 - 2270 *
DATABASE PROTEIN NCBI; 3 October 2003 (2003-10-03), Database accession no. AAQ89380 *
DATABASE UNIPROTKB NCBI; 10 June 2008 (2008-06-10), "Uncharacterized protein UNQ773/PR01567", Database accession no. Q96DA0 *
KIM, S. A. ET AL.: "Pancreatic adenocarcinoma up-regulated factor(PAUF), a no vel up-regulated secretory protein in pancreatic ductal adenocarcinoma.", CANCER SCIENCE., vol. 100, no. 5, 2 March 2009 (2009-03-02), pages 828 - 836 *

Also Published As

Publication number Publication date
WO2010036031A2 (fr) 2010-04-01
KR20100034720A (ko) 2010-04-01
KR101098186B1 (ko) 2011-12-23
KR20110122807A (ko) 2011-11-11

Similar Documents

Publication Publication Date Title
CY1115572T1 (el) Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
WO2007067992A3 (fr) Anticorps monoclonaux humains se liant au fucosyl-gm1, et procedes d'utilisation de l'anti-fucosyl-gm1
BR112014010161A2 (pt) anticorpo monoclonal antiproteína de ligação ao dna tar de 43 kda (tdp-43) e seus método de preparação e uso no tratamento de proteinopatia tdp-43, bem como composições, polinucleotídeo, método in vitro e kit para diagnosticar proteinopatia tdp-43
WO2009085216A3 (fr) Compositions et méthodes de détection ou d'élimination de cellules sénescentes pour le diagnostic ou le traitement de maladies
WO2008088854A3 (fr) Marqueurs génétiques pour la prédiction de sensibilité à une polythérapie
WO2008070672A3 (fr) Compositions et procédés pour le traitement du cancer avec des cuprédoxines et de l'adn riche en cpg
MX2012004084A (es) Anticuerpos siglec-15 para tratar enfermedad relacionada con perdida osea.
WO2005100998A3 (fr) Marqueurs membranaires destines a etre utilises pour le diagnostic et le traitement du cancer
BRPI0412567A (pt) anticorpo humano isolado, método de tratamento de uma condição causada pela expressão aumentada de ngf ou pela sensibilidade aumentada ao ngf em um paciente, composição farmacêutica, método para detectar ngf em uma amostra biológica, molécula de ácido nucleico, célula hospedeira, linhagem celular isolada, agente de ligação especìfica em ngf, anticorpo humano isolado ou fragmento de imunoglobulina imunologicamente funcional ou um ligante de antìgeno do mesmo, polinucleotìdeo, vetor de expressão, medicamento para tratar um distúrbio doloroso ou uma condição associada com a expressão aumentada de ngf ou a sensibilidade aumentada ao ngf, e, uso de uma quantidade farmaceuticamente efetiva de anticorpo
AR085955A1 (es) Proteinas de union al antigeno
MX2008009886A (es) Anticuerpos que enlazan par-2.
EA200870594A1 (ru) Связывающие человеческие молекулы с киллерной активностью в отношении энтерококков и их применение
EP3530736A3 (fr) Anticorps monoclonaux humains pour mort programmée 1 (pd-1) et procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 seuls ou combinés à d'autres formulations immunothérapeutiques
MX343748B (es) Anticuerpos neutralizantes anti-ngf humanos como inhibidores selectivos de la trayectoria ngf.
BRPI0822162A2 (pt) Método para tratamento de doenças das unhas ou leito ungueal e composição farmacêutica para tratamento tópico de doença das unhas ou leito ungueal.
WO2010059969A3 (fr) Thérapie antiangiogenèse pour le traitement du cancer du sein
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
JP2008530137A5 (fr)
WO2009106819A3 (fr) Matériaux biologiques et leurs utilisations
CY1115349T1 (el) Εξανθρωπισμενα αντι cxcr4 αντισωματα για τη θεραπεια καρκινου
MX2012012075A (es) Moleculas y metodos para usarlas para tratar enfermedades asociadas con ligandos erbb/erbb.
WO2005040421A3 (fr) Marqueurs de pronostic et de diagnostic des troubles de proliferation cellulaire dans les tissus mammaires
EA201591219A1 (ru) Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
WO2010036031A3 (fr) Anticorps monoclonal humain specifique au pauf, composition pharmaceutique destinee au traitement du cancer le comprenant et procede l'utilisant pour detecter le cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09816424

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09816424

Country of ref document: EP

Kind code of ref document: A2